...in patients with SLE ... E-C4d levels, but not serum C4 levels, were associated with disease activity... Recent evidence suggests that measurement of the erythrocyte-bound complement activation ...

Please provide your email address to receive an email when new articles are posted on . Erythrocyte-bound C4d, a biomarker for systemic lupus erythematosus patented by Exagen Diagnostics, is useful in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A commercially ...

Renal involvement, high baseline proteinuria, hypoalbuminemia, and C3 consumption were robust determinants of impending renal flares in SLE. Investigators have identified characteristics that signal ...

Exagen, a life science company serving the rheumatology specialty, and the Lupus Foundation of America, the national force devoted to solving the mystery of lupus, announced a new initiative to ...

In a new study, researchers identify biomarkers that may predict the efficacy of low-dose IL-2 (Ld-IL2) treatment in people with systemic lupus erythematosus (SLE). IL-2 stands for interleukin-2 – a ...

THE development of lupus cells in patients with systemic lupus erythematosus has been difficult to study, and only limited information is available. The extent to which the L.E.-cell phenomenon occurs ...